Serum Laminin-<i>γ</i>2 as a Novel Biomarker for Colorectal Cancer

DOI
  • Kiyokawa Hirofumi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Yasuda Hiroshi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Oikawa Ritsuko
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Ishii Toshiya
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Yamamoto Hiroyuki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Tsukikawa Satoshi
    Division of Gastroenterological and General Surgery, St. Marianna University School of Medicine
  • Otsubo Takehito
    Division of Gastroenterological and General Surgery, St. Marianna University School of Medicine
  • Minegishi Tomoko
    Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo
  • Koshikawa Naohiko
    Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo
  • Seiki Motoharu
    Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo Kanazawa University Graduate School of Medical Science
  • Itoh Fumio
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine

Bibliographic Information

Other Title
  • 大腸癌における新規バイオマーカーとしての血清ラミニン<i>γ</i>2単鎖測定法の開発

Search this article

Description

Background: A clinically significant tumor marker is important for the diagnosis of colorectal cancer (CRC) and its management after the treatment. Laminin (Ln)-γ2 is expressed in various types of malignant carcinomas, indicating that it may be a potential serum biomarker. We recently developed a quantitative ELISA assay to determine serum Ln-γ2 levels using the monoclonal antibody to human Ln-γ2 selectively.<br/>Methods: Using our previously developed ELISA assay, we examined the serum Ln-γ2 levels in 78 serum specimens from 51 healthy volunteers, 8 patients with benign disease, and 19 CRC patients. Using chemiluminescent immunoassays, we measured carcinoembryonic antigen (CEA) and CA19-9 simultaneously and compared the diagnostic value of a combination of Ln-γ2 with each of these markers.<br/>Results: The medians of the serum levels of Ln-γ2 in healthy controls, benign disease patients, and CRC patients were 241.9 pg/mL, 138.8 pg/mL, and 323.0 pg/mL, respectively. Significantly higher Ln-γ2 levels were observed in patients with CRC than in the other two groups. The optimal cutoff value for Ln-γ2 that would distinguish CRC cases from non-malignant cases was 315.8 pg/mL. We observed elevated Ln-γ2 levels (>315.8 pg/mL) in 57.9% of the patients with CRC. The positive rate in patients with CRC for the combination of Ln-γ2 and CEA was 78.9%, higher than that for either of those markers alone (57.9% and 52.6%). The positive rate in CRC patients was high for all markers in advanced stage CRC, but that for CEA and CA19-9 in Stage I/II was low. On the other hand, the positive rate for Ln-γ2 in Stage I/II was high at 50.0%.<br/>Conclusions: Serum Ln-γ2 may be a novel biomarker for CRC that can be used along with existing tumor markers for CRC detection.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top